- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Pembrolizumab (urothelial cancer) – November 2017
Pembrolizumab (urothelial cancer): Powder for injection 50 mg, Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
16 March 2018